Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

BACKGROUND. Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR‐1 and ‐2), respectively. This open‐label, randomized phase II study evaluated their efficacy and safety in combination with capecitabine (CAP) in patients with previously treated...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Vahdat, Linda T., Layman, Rachel, Yardley, Denise A., Gradishar, William, Salkeni, Mohamad A., Joy, Anil Abraham, Garcia, Agustin A., Ward, Patrick, Khatcheressian, James, Sparano, Joseph, Rodriguez, Gladys, Tang, Shande, Gao, Ling, Dalal, Rita P., Kauh, John, Miller, Kathy
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2017
主題:
Breast Cancer
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344637/
https://ncbi.nlm.nih.gov/pubmed/28220020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0265
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料